ABIO Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (26 Apr 2024 @ 16:00):

ARCA biopharma, Inc., a clinical-stage biopharmaceutical company, develops and commercializes genetically targeted therapies for cardiovascular diseases...

Stats
Today's Volume	85 291.00
Average Volume	1.42M
Market Cap	51.91M
EPS	$0 ( 2024-04-24 )
Next earnings date	( $0 ) 2024-07-19
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-9.68
ATR14	$0.0140 (0.39%)

Insider Trading

Date	Person	Action	Amount	type
2024-01-30	Ma-weaver Jacob	Buy	6 000	Stock option (right to buy)
2024-01-30	Hove Anders D	Buy	6 000	Stock Option (right to buy)
2024-01-30	Mitchell Daniel J	Buy	6 000	Stock Option (right to buy)
2024-01-30	Flynn James P	Buy	6 000	Stock Option (right to buy)
2024-01-30	Conway Robert E	Buy	6 000	Stock Option (right to buy)

INSIDER POWER
98.20
Last 95 transactions
Buy: 2 938 848 \| Sell: 17 694 644

Volume Correlation

Long: 0.30 (neutral)

Short: -0.21 (neutral)

Signal:(41.095) Neutral

ARCA Biopharma Inc Correlation

10 Most Positive Correlations
AMRB	0.928
SQQQ	0.923
SGH	0.909
SBNYP	0.909
PMVP	0.909
XPEL	0.907
SPRB	0.903
SMTC	0.899
ALDX	0.895
WTBA	0.891

10 Most Negative Correlations
AMD	-0.923
PRVB	-0.92
QQQM	-0.918
QQQ	-0.918
OSIS	-0.918
CIFR	-0.916
CYN	-0.915
NVEI	-0.913
DRNA	-0.912
SMH	-0.911

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

ARCA Biopharma Inc Correlation - Currency/Commodity

-0.58
( weak negative )

0.02
( neutral )

0.00
( neutral )

-0.57
( weak negative )

0.00
( neutral )

0.60
( weak )

ARCA Biopharma Inc Financials

Annual	2023
Revenue:	$0
Gross Profit:	$-111 000 (0.00 %)
EPS:	$-0.370

FY	2023
Revenue:	$0
Gross Profit:	$-111 000 (0.00 %)
EPS:	$-0.370

FY	2022
Revenue:	$0
Gross Profit:	$-114 000 (0.00 %)
EPS:	$-0.640

FY	2021
Revenue:	$0.00
Gross Profit:	$0.00 (0.00 %)
EPS:	$-1.390

Financial Reports:

No articles found.

ARCA Biopharma Inc

ARCA biopharma, Inc., a clinical-stage biopharmaceutical company, develops and commercializes genetically targeted therapies for cardiovascular diseases. Its lead product candidates are Recombinant Nematode Anticoagulant Protein c2 (rNAPc2) (AB201), which is in Phase IIb clinical trial for the treatment for COVID-19; and Gencaro (bucindolol hydrochloride), a pharmacogenetically-targeted beta-adrenergic receptor antagonist that has completed Phase IIb trial for the treatment of atrial fibrillation in patients with chronic heart failure. ARCA biopharma, Inc. has a collaboration agreement with LabCorp to develop genetic test for GENETIC-AF clinical trial; and research collaboration with Colorado Prevention Center, the University of Colorado's Academic Research Organization to develop and commercialize Gencaro. The company was incorporated in 2004 and is headquartered in Westminster, Colorado.